Clinical Trials Logo

Regional Citrate Anticoagulation clinical trials

View clinical trials related to Regional Citrate Anticoagulation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04959110 Completed - Pharmacokinetic Clinical Trials

Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT

Citrate PK
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA).

NCT ID: NCT04792424 Completed - Clinical trials for Continuous Renal Replacement Therapy

No Monitoring of Post-filter Ionized Calcium in Regional Citrate Anticoagulation

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Do no monitor of post-circuit ionized calcium affact the filter life time of continueous renal replacement therapy with regional citrate anticoagulation circuit? A randomized control trial

NCT ID: NCT04071171 Completed - Acute Kidney Injury Clinical Trials

Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

The primary objectives of the BiPhox-Trial are to demonstrate, that the use of Biphozyl® as a replacement fluid in adult critically ill acute kidney injury (AKI) patients, results in a lower rate of pH excursions and of bicarbonate (HCO3-) excursions compared to the use of Phoxilium® during the studied continuous veno-venous hemofiltration (CVVH) interval with regional citrate anticoagulation (RCA). The secondary objectives of the BiPhox-Trial are to evaluate the time to pH level normalization and the HCO3- substitution rates after initiation of CVVH treatment. Further, to demonstrate that the use of Biphozyl® as a replacement fluid in adult critically ill AKI patients, results in a more stable acid-base-status as well as improved respiratory situation due to lower intracorporeal HCO3- and carbon dioxide levels compared to the use of Phoxilium® during the studied CVVH interval with RCA.